Polycyclo Ring System Having The Diazine Ring As One Of The Cyclos Patents (Class 544/245)
  • Patent number: 10214525
    Abstract: The present invention relates to chlorinated naphthalenetetracarboxylic acid derivatives, preparation thereof and use thereof as charge transport materials, exciton transport materials or emitter materials.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: February 26, 2019
    Assignee: BASF SE
    Inventors: Martin Koenemann, Gabriele Mattern, Frank Wuerthner, Cornelia Goepfert, Ruediger Schmidt
  • Patent number: 9630973
    Abstract: The present invention provides the compounds of formulae (3) and (1) wherein n is 0 or 1, R13 and R14 are the same or different and are selected from the group consisting of NHR310, NR311R312, OR313, SR314 and R315, or R13 and R14 together are selected from the group consisting of (a), (b) and (c), and X is CI, Br of I, and a process for the preparation of compounds of formula (3) comprising the compounds of formula (1) as key intermediates.
    Type: Grant
    Filed: August 27, 2013
    Date of Patent: April 25, 2017
    Assignees: BASF SE, Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Henrike Wonneberger, Helmut Reichelt, Yulian Zagranyarski, Chen Li, Klaus Muellen, Long Chen
  • Patent number: 9204598
    Abstract: Disclosed is a wavelength-conversion material, and methods for its use, that includes an organic fluorescent dye and a polymeric matrix, wherein the organic fluorescent dye is solubilized in the polymeric matrix, and wherein the polymeric matrix is capable of absorbing light comprising a wavelength of 500 to 700 nm and emitting the absorbed light at a wavelength of greater than 550 to 800 nm.
    Type: Grant
    Filed: July 9, 2013
    Date of Patent: December 8, 2015
    Assignee: Saudi Basic Indsutries Corporation
    Inventors: Suresh Velate, Pradeep Jeevaji Nadkarni, M. Meerakani Sait, Vinod Kumar Vasudevan, Sankaran Nedumbamana
  • Patent number: 9034485
    Abstract: The present invention relates to compounds of the formula (1) and to the use thereof in organic electronic devices, and to organic electronic devices which comprise compounds of the formula (1), preferably as hole-transport materials and/or as emitting materials.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: May 19, 2015
    Assignee: Merck Patent GmbH
    Inventors: Arne Buesing, Holger Heil, Philipp Stoessel, Amir Hossain Parham, Rocco Fortte, Jonas Valentin Kroeber
  • Patent number: 9034655
    Abstract: Luminescent labels based on aromatic and heterocyclic compounds, including reactive intermediates used to synthesize these compounds, and methods of synthesizing and using these reporter compounds. These labels combine high photostabilities, large Stokes' shifts and contain a pyrimidinium moiety as a water-soluble group. These luminescent compounds relate generally to the following structure: The methods relate generally to the synthesis and/or use of reporter compounds for fluorescence lifetime or fluorescence polarization based applications.
    Type: Grant
    Filed: October 18, 2010
    Date of Patent: May 19, 2015
    Assignee: SETA BioMedicals, LLC
    Inventors: Leonid D. Patsenker, Inna G. Yermolenko, Iryna A. Fedyunyaeva, Yelena N. Obukhova, Olga N. Semenova, Ewald A. Terpetschnig
  • Patent number: 8993595
    Abstract: Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula Ia or Ib, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.
    Type: Grant
    Filed: January 10, 2013
    Date of Patent: March 31, 2015
    Assignee: Idenix Pharmaceuticals, Inc.
    Inventors: Christophe Claude Parsy, Francois-Rene Alexandre, Michel Derock, Frederic Leroy, Jean-Christophe Meillon, Thierry Convard, Dominique Surleraux
  • Patent number: 8940412
    Abstract: An organic electroluminescence device and a material for producing the organic electroluminescence device. The organic electroluminescence device includes an organic thin film layer between a cathode and an anode, the organic thin film layer including one or more layers, in which the organic thin film layer includes one or more light emitting layers and at least one of the light emitting layers includes a phosphorescent material and a host material. The host material has an essential structure in which a naphthalene ring is bonded to a fluorene skeleton, dibenzofuran skeleton, or dibenzothiophene skeleton. The organic electroluminescence device is a phosphorescent device having high efficiency and long lifetime.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: January 27, 2015
    Assignee: Idemitsu Kosan Co., Ltd.
    Inventors: Yoriyuki Takashima, Toshihiro Iwakuma, Toshinari Ogiwara, Chishio Hosokawa, Mitsunori Ito
  • Patent number: 8920944
    Abstract: Use of a precursor of an n-dopant for doping an organic semiconductive material, as a blocking layer, as a charge injection layer, as an electrode material, as a storage material or as a semiconductor material itself in electronic or optoelectronic components, the precursor being selected from the following formulae 1-3c:
    Type: Grant
    Filed: June 20, 2008
    Date of Patent: December 30, 2014
    Assignee: Novaled AG
    Inventors: Michael Limmert, Andrea Lux, Horst Hartmann
  • Patent number: 8895734
    Abstract: The present invention provides a novel class of peptide nucleic acid derivatives, which show good cell penetration and strong binding affinity for nucleic acid.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: November 25, 2014
    Assignee: OliPass Corporation
    Inventors: Shin Chung, Heui-Yeon Kim, Hyun-Jin Park, Mi-Ran Kim, Jong-Ook Lee
  • Patent number: 8884008
    Abstract: The present invention provides a novel class of peptide nucleic acid derivatives, which show good cell penetration and strong binding affinity for nucleic acid.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: November 11, 2014
    Assignee: OliPass Corporation
    Inventors: Shin Chung, Heui-Yeon Kim, Hyun-Jin Park, Mi-Ran Kim, Jong-Ook Lee
  • Publication number: 20140329674
    Abstract: The present specification discloses honeybee repellents exhibiting repellent properties similar to 2-heptanone, compositions comprising such repellents, uses to repel a honeybee from a mammal, location, plant, structure treated of such repellents, and methods of treating a mammal, location, plant, structure by applying such repellents.
    Type: Application
    Filed: May 3, 2014
    Publication date: November 6, 2014
    Applicant: INSCENT, INC.
    Inventors: Daniel F. Woods, Spiros Dimitratos, Robin W. Justice
  • Patent number: 8859766
    Abstract: The present invention provides a novel class of peptide nucleic acid derivatives, which show good cell penetration and strong binding affinity for nucleic acid.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: October 14, 2014
    Assignee: OliPass Corporation
    Inventors: Shin Chung, Heui-Yeon Kim, Hyun-Jin Park, Mi-Ran Kim, Jong-Ook Lee
  • Publication number: 20140291652
    Abstract: An organic electroluminescent element using a compound represented by the following general formula (I) emits dark blue light and has small changes in the chromaticity and in the driving voltage even after driving for a long period of time: wherein R1 to R6; Q1 and Q2; X1, X2, X3 and X4 are as defined herein.
    Type: Application
    Filed: August 6, 2012
    Publication date: October 2, 2014
    Applicant: UDC IRELAND LIMITED
    Inventors: Saki Takada, Koji Takaku, Tetsu Kitamura, Toshihiro Ise, Wataru Sotoyama
  • Publication number: 20140256717
    Abstract: There is provided compounds of formula I, wherein R1, R2a, R2b, R2c, X, Y, Z, R3 and ring A/B have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. PI3-K, particularly class I PI3K, PIM family kinase and/or mTOR) is desired and/or required, and particularly in the treatment of cancer. The invention also relates to combinations containing such compounds.
    Type: Application
    Filed: May 18, 2012
    Publication date: September 11, 2014
    Applicant: Centro Nacional de Investigaciones Oncológicas (CNIO)
    Inventors: Joaquín Pastor Fernández, Rosa Maria Álvarez Escobar, Rosario Concepción Riesco Fagundo, Ana Belén García García, Antonio Rodríguez Hergueta, Jose Ignacio Martin Hernando, Carmen Blanco Aparicio, David Álvaro Cebrián Muñoz
  • Patent number: 8829014
    Abstract: Thiazole and thiophene compounds are disclosed having utility in treating inflammatory conditions, immunoinflammatory conditions, autoimmune diseases, and cancers. Methods for the synthesis of these compounds are also disclosed.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: September 9, 2014
    Assignees: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, B.V. Patel Pharmaceutical Education & Research Development (PERD) Centre
    Inventors: Anthony Giordano, Kamala K. Vasu, Hardik M. Thakar, Rajan S. Giri, Vasudevan Sudarsanam, Swapnil G. Yerande, Gajanan S. Inamdar
  • Patent number: 8815417
    Abstract: A heterocyclic compound represented by Formula 1 below and an organic light-emitting device including the heterocyclic compound: wherein R1 to R12 are defined as in the specification.
    Type: Grant
    Filed: August 16, 2011
    Date of Patent: August 26, 2014
    Assignee: Samsung Display Co., Ltd.
    Inventors: Young-Kook Kim, Seok-Hwan Hwang, Yoon-Hyun Kwak, Sun-Young Lee, Hye-Jin Jung, Jin-O Lim, Jong-Hyuk Lee
  • Patent number: 8795691
    Abstract: The present invention is directed to implants and the modification of the surface of implants using amino acid or polypeptide functionalized rosette nanotubes.
    Type: Grant
    Filed: March 16, 2011
    Date of Patent: August 5, 2014
    Assignees: Brown University, National Research Council of Canada, The Governors of the University of Alberta
    Inventors: Thomas J. Webster, Hicham Fenniri, Usha Devi Hemraz
  • Publication number: 20140200333
    Abstract: Dendronic reporters are described which incorporate a high density of luminescent or non-luminescent dyes at periphery sites and a focal point group that is reactive, ionic or a conjugated substance. Such dendronic reporters are capable of sensing analytes, or are otherwise useful in luminescent assays. Additionally, methods of synthesis are described.
    Type: Application
    Filed: August 14, 2012
    Publication date: July 17, 2014
    Applicant: SETA BIOMEDICALS, LLC
    Inventors: Ewald Terpetschnig, Inna G. Yermolenko, Olena M. Obukhova, Anatoliy Tatarets, Leonid D. Patsenker
  • Publication number: 20140155603
    Abstract: The invention relates to compounds of the formula (I) in which Y1 and Y2 are each O or, respectively, NRa or NRb, where Ra and Rb are each H or organyl; Z1 to Z4 are each O or S; R11 to R14, R21 to R24 are each Cl, F; where 1 or 2 of the R11 to R14, R21 to R24 radicals may also be CN and/or 1 R11 to R14, R21 to R24 radical may be H; and where, when Y1 is NRa, Z1 or Z2 may also be NRc, where Ra and Rc together are a bridging X group having from 2 to 5 atoms; and where, when Y2 is NRb, Z3 or Z4 may also be NRd, where Rb and Rd together are a bridging X group having from 2 to 5 atoms; to a process for preparation thereof, and to their use as emitter materials, charge transport materials or exciton transport materials.
    Type: Application
    Filed: January 17, 2014
    Publication date: June 5, 2014
    Applicant: BASF SE
    Inventors: Martin Koenemann, Gabriele Mattern, Gerd Weber
  • Patent number: 8691187
    Abstract: Imaging agents of formulas (I)-(V) and methods for detecting neurological disorders comprising administering to a patient in need compounds of formulas (I)-(V) capable of binding to tau proteins and ?-amyloid peptides are presented herein. The invention also relates to methods of imaging A? and tau aggregates comprising introducing a detectable quantity of pharmaceutical formulation comprising a radiolabeled compound of formulas (I)-(V) and detecting the labeled compound associated with amyloid deposits and/or tau proteins in a patient. These methods and compositions enable preclinical diagnosis and monitoring progression of AD and other neurological disorders.
    Type: Grant
    Filed: February 25, 2011
    Date of Patent: April 8, 2014
    Assignee: Eli Lilly and Company
    Inventors: Anna Katrin Szardenings, Wei Zhang, Dhanalakshmi Kasi, Anjana Sinha, Umesh B. Gangadharmath, Joseph C. Walsh
  • Patent number: 8669264
    Abstract: The teachings provided herein generally relate to compositions comprising rutaecarpine derivatives that activates CYP1A2 through enzyme induction. The uses for such a derivative can include removing caffeine from a subject, improving sleep, treating insomnia, treating caffeine toxicity, treating caffeine addiction and withdrawal symptoms, and the like. Caffeine is just one example of a substrate that can be removed using the derivatives taught herein, and other examples, including theophylline, are provided herein.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: March 11, 2014
    Assignee: Linnet Biopharmaceuticals, Inc.
    Inventors: Liang Xue, William K. Chan, Stan W. Linnet, Timothy N. Linnet
  • Publication number: 20140001458
    Abstract: Provided are a nitrogen-containing aromatic compound useful for an organic electroluminescent device, and an organic electroluminescent device (organic EL device) that improves luminous efficiency of the device and sufficiently ensures driving stability of the device. The nitrogen-containing aromatic heterocyclic compound is represented by the following formula (1). The organic EL device includes an organic layer that contains the nitrogen-containing aromatic heterocyclic compound between an anode and a cathode laminated on a substrate. In the formula (1), a ring A represents an aromatic ring represented by the formula (1a) and fused with two adjacent rings, a ring B represents a heterocycle represented by the formula (1b) and fused with two adjacent rings, Y's each represent C—R or N, X's each represent N—Z, O, S, or Se, R represents hydrogen, an alkyl group, an aromatic group, or the like, and Z represents an alkyl group, an aromatic group, or the like.
    Type: Application
    Filed: February 9, 2012
    Publication date: January 2, 2014
    Inventors: Takaya Ishiyama, Hiroyuki Hayashida, Mitsuru Sakai, Masashi Niina, Kazuto Shiraishi, Kazuaki Yoshimura
  • Publication number: 20140005390
    Abstract: A tetraazaperopyrene compound of formula (I): wherein: R1, R2, R3, R4, R5, R6, R7, R8 at each occurrence, independently are selected from H, Cl and Br, with the proviso that at least one of R 1, R2, R3, R4, R5, R6, Wand R8 is Cl or Br, R9, R10, at each occurrence, independently are selected from H, a C1-30 alkyl group, a C1-30 haloalkyl group, a C6-14 aryl group, a heteroaryl group having 5 to 14 ringatoms, and a C7-20 arylalkyl group, wherein aryl, heteroaryl and arylalkyl can be optionally substituted with one or more halogen, C1-4 haloalkyl, —CN, —NO2, —CHO, —COOH, —CONH2, —CO(C1-14 alkyl), —COO(C1-14 alkyl), —CONHC(C1-14 alkyl) and —CON(C1-14 alkyl)2 groups.
    Type: Application
    Filed: March 2, 2012
    Publication date: January 2, 2014
    Applicant: BASF SE
    Inventors: Lutz Gade, Susanne Martens, Sonja Geib
  • Patent number: 8604032
    Abstract: Provided herein are compounds of formula (I), pharmaceutical compositions comprising the compounds, and methods of use thereof The compounds provided herein modulate kinase activity, including PI3 kinase activity, and are useful for treating diseases and conditions associated with kinase activity, including diseases and conditions associated with PI3 kinase activity.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: December 10, 2013
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Pingda Ren, Yi Liu, Liansheng Li, Katrina Chan, Alfredo C. Castro, Catherine A. Evans
  • Patent number: 8606529
    Abstract: The application relates to methods and systems for analysis of dissociation behavior of nucleic acids and identification of nucleic acids. In one aspect, methods and systems are disclosed for identifying a nucleic acid in a sample including an unknown nucleic acid and for detecting a single nucleotide polymorphism in a nucleic acid in a sample. Methods and systems are also disclosed for identification of a nucleic acid in a biological sample including at least one unknown nucleic acid by fitting denaturation data including measurements of a quantifiable physical change of the sample at a plurality of independent sample property points to a function to determine an intrinsic physical value and to obtain an estimated physical change function, and identifying the nucleic acid in the biological sample by comparing the intrinsic physical value for at least one unknown nucleic acid to an intrinsic physical value for a known nucleic acid.
    Type: Grant
    Filed: March 26, 2012
    Date of Patent: December 10, 2013
    Assignee: Canon U.S. Life Sciences, Inc.
    Inventors: Deborah Boles, Kenton C. Hasson, Sami Kanderian
  • Patent number: 8598148
    Abstract: The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The modular synthesis of tetracyclines and tetracycline analogs described provides an efficient and enantioselective route to a variety of tetracycline analogs and polycyclines previously inaccessible via earlier tetracycline syntheses and semi-synthetic methods. These analogs may be used as anti-microbial agents or anti-proliferative agents in the treatment of diseases of humans or other animals.
    Type: Grant
    Filed: May 12, 2010
    Date of Patent: December 3, 2013
    Assignee: President and Fellows of Harvard College
    Inventors: Andrew G. Myers, Mark G. Charest, Christian D. Lerner, Jason D. Brubaker, Dionicio R. Siegel
  • Patent number: 8597801
    Abstract: A heterocyclic compound includes compounds represented by Formula 1 or Formula 2 below:
    Type: Grant
    Filed: August 25, 2011
    Date of Patent: December 3, 2013
    Assignee: Samsung Display Co., Ltd.
    Inventors: Yoon-Hyun Kwak, Seok-Hwan Hwang, Young-Kook Kim, Sun-Young Lee, Hye-Jin Jung, Jin-O Lim, Sang-Hyun Han, Hee-Joo Ko, Jong-Hyuk Lee
  • Publication number: 20130285036
    Abstract: The present invention relates to aromatic nitrogen heterocycles, and to electronic devices, in particular organic electroluminescent devices, which comprise these aromatic nitrogen heterocycles, in particular in a hole-injection layer and/or in a hole-transport layer and/or in a hole-blocking layer and/or in an electron-transport layer and/or in an emitting layer.
    Type: Application
    Filed: December 15, 2011
    Publication date: October 31, 2013
    Applicant: MERCK PATENT GMBH
    Inventors: Philipp Stoessel, Arne Buesing, Esther Breuning, Christof Pflumm, Amir Hossain, Thomas Eberle, Teresa Mujica-Fernaud
  • Patent number: 8551237
    Abstract: A process for preparing colorants of the general formula (Ia), (Ib) or (Ic) or mixtures thereof, comprises reacting (a) tetracarboxylic acids or their functional derivatives with (b) at least one compound selected from i. aliphatic amines, ii. aromatic amines, iii. aliphatic diamines, iv. aromatic diamines, (c) optionally in the presence of further additives, (d) optionally in the presence of wetting agents in a mixing apparatus. These colorants are useful for coloration of macromolecular organic and inorganic materials of natural and synthetic origin.
    Type: Grant
    Filed: December 4, 2008
    Date of Patent: October 8, 2013
    Assignee: BASF SE
    Inventor: Johannes Loebel
  • Patent number: 8541423
    Abstract: The present application relates to compounds and methods for treating pain, incontinence and other conditions.
    Type: Grant
    Filed: April 11, 2012
    Date of Patent: September 24, 2013
    Assignee: Hydra Biosciences, Inc.
    Inventors: Magdalene M. Moran, Christopher Fanger, Jayhong A. Chong, Colleen McNamara, Xiaoguang Zhen, Josh Mandel-Brehm
  • Patent number: 8507500
    Abstract: This document relates to compounds as well as methods and materials involved in modulating neurotransmitter reuptake. For example, compounds, methods for synthesizing compounds, and methods for inhibiting neurotransmitter reuptake are provided.
    Type: Grant
    Filed: August 23, 2012
    Date of Patent: August 13, 2013
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Elliott Richelson, Abdul H. Fauq
  • Patent number: 8501749
    Abstract: Disclosed are small molecule inhibitors of the formula (I), which are useful in treating various diseases and conditions involving chymase.
    Type: Grant
    Filed: January 26, 2010
    Date of Patent: August 6, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Xin Guo, Chuk Chui Man, Hidenori Takahashi
  • Publication number: 20130168321
    Abstract: An activated carbon material for removing a contaminant from a liquid. The activated carbon material can be a plurality carbon grains that have a pore volume of approximately 0.1 milliliters per gram (mL/g) in the range of less than about 15 angstroms in width. The carbon grains can also have or contain a nitrogen-containing species having a concentration of more than 2 atomic percent nitrogen. A plurality of the carbon grains can be used to make a contactor that is operable to remove or reduce perchlorate having a concentration of 20 parts per billion (ppb) to less than 4 ppb from 4,500 bed volumes of water with the nitrogen-containing species leaching off of the carbon grains less than 0.1 mg/L. The activated carbon material can also be electrochemically regenerated.
    Type: Application
    Filed: January 3, 2013
    Publication date: July 4, 2013
    Applicant: THE PENN STATE RESEARCH FOUNDATION
    Inventor: THE PENN STATE RESEARCH FOUNDATION
  • Patent number: 8450482
    Abstract: Processes for the preparation of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline, salts thereof, and the intermediates used in the process are described.
    Type: Grant
    Filed: April 22, 2010
    Date of Patent: May 28, 2013
    Assignee: Astrazeneca AB
    Inventors: Kay Alison Boardman, Oliver Robert Cunningham, William Robert Fraser Goundry, David Dermot Patrick Laffan
  • Publication number: 20130123495
    Abstract: The invention relates to compounds of the formula (I) in which Y1 and Y2 are each O or, respectively, NRa or NRb, where Ra and Rb are each H or organyl; Z1 to Z4 are each O or S; R11 to R14, R21 to R24 are each Cl, F; where 1 or 2 of the R11 to R14, R21 to R24 radicals may also be CN and/or 1 R11 to R14, R21 to R24 radical may be H; and where, when Y1 is NRa, Z1 or Z2 may also be NRc, where Ra and Rc together are a bridging X group having from 2 to 5 atoms; and where, when Y2 is NRb, Z3 or Z4 may also be NRd, where Rb and Rd together are a bridging X group having from 2 to 5 atoms; to a process for preparation thereof, and to their use as emitter materials, charge transport materials or exciton transport materials.
    Type: Application
    Filed: January 4, 2013
    Publication date: May 16, 2013
    Inventors: Martin KOENEMANN, Gabriele Mattern, Gerd Weber
  • Patent number: 8377962
    Abstract: Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula Ia or Ib, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.
    Type: Grant
    Filed: April 7, 2010
    Date of Patent: February 19, 2013
    Assignee: Idenix Pharmaceuticals, Inc.
    Inventors: Christophe Claude Parsy, Francois-Rene Alexandre, Michel Derock, Frederic Leroy, Jean-Christophe Meillon, Thierry Convard, Dominique Surleraux
  • Publication number: 20130039904
    Abstract: The present invention discloses a gamboge acid cyclization analogs, their preparation methods and applications by semi-synthesis with the following structural formula I-III: Where ring A, ring B or/and ring C is 4-10 membered saturated or/and unsaturated aliphatic ring aliphatic heterocycle or aryl heterocycle. R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 or/and R12 is, independently at each occurrence, optionally substituted substituent of glycosyl, multi-hydroxyl, amino acid, acyloxy, phosphoric acid oxy, sulfonyloxy, alkoxy, aryloxy, heterocyclic oxy, thiol, aliphatic or cyclic group containing oxygen, sulfur, nitrogen or phosphorus, one of the substituents or combinations thereof. The present invention has antitumor activity management, antiviral, antibacterial and antifungal activity management, as anti-tumor, anti-viral, immune, antibacterial and antifungal agents, with other known anti-tumor, anti-viral, immune, together with the application of antibacterial and antifungal.
    Type: Application
    Filed: August 2, 2010
    Publication date: February 14, 2013
    Applicant: Liaoning Lifeng Scientific & Technology Development Company Ltd.
    Inventor: Lifeng Xu
  • Publication number: 20120322816
    Abstract: The teachings provided herein generally relate to compositions comprising rutaecarpine derivatives that activates CYP1A2 through enzyme induction. The uses for such a derivative can include removing caffeine from a subject, improving sleep, treating insomnia, treating caffeine toxicity, treating caffeine addiction and withdrawal symptoms, and the like. Caffeine is just one example of a substrate that can be removed using the derivatives taught herein, and other examples, including theophylline, are provided herein.
    Type: Application
    Filed: June 17, 2011
    Publication date: December 20, 2012
    Inventors: LIANG XUE, William K. Chan, Stan W. Linnet, Timothy N. Linnet
  • Publication number: 20120283220
    Abstract: The present invention provides compounds of Formula (I-IV): compositions containing the same, and methods of use thereof such as for the treatment of cancer.
    Type: Application
    Filed: September 22, 2010
    Publication date: November 8, 2012
    Inventors: Kuo-Hsiung Lee, Xiaoming Yang, Qian Shi, Kenneth F. Bastow, Che-Ming Teng, Tse-Ming Hong, Pan-Chyr Yang, Shuenn-Chen Yang
  • Patent number: 8247422
    Abstract: The invention relates to the use of a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for use in modulating an immune or inflammatory response: wherein: Z=O or S; n=1-3; R3=—CO2R8, —C(O)SR8, —C(O)NHR8, —C(S)OR8, —C(S)SR8, —C(S)NHR8, —C(NH)SR8 or —C(NH)NHR8, wherein R8 is —H or alkyl; R4=—H, —CH2R5 or —CH2CH2R5, wherein R5 independently has one of the meanings of R3; B=—NR2—, —CH2NR2—, —CH2CH2NR2—, —CH2CHR7— or —CH2O—, wherein R2 is H or a C1-3 alkyl, alkenyl or alkynyl group, and R7 is H or a C1-3 alkyl or alkoxy group; A=wherein R1=—NH2 or —OH, C and D are each, independently, a 5- or 6-membered, substituted or unsubstituted, aromatic or non-aromatic ring which may also contain one or more heteroatoms, and C is connected to group B in any available position.
    Type: Grant
    Filed: February 13, 2008
    Date of Patent: August 21, 2012
    Inventor: Dan Stoicescu
  • Patent number: 8242122
    Abstract: The invention is directed to methods and compositions for inhibiting caspase-independent apoptosis. In particular, methods and compositions for inhibiting Omi/HtrA2 activity, as well as method for identifying other inhibitors of Omi/HtrA2. Also disclosed are Omi/HtrA2 specific substrates and methods for identifying other substrates of Omi/HtrA2.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: August 14, 2012
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventor: Antonis S. Zervos
  • Patent number: 8236950
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.
    Type: Grant
    Filed: December 19, 2007
    Date of Patent: August 7, 2012
    Assignee: Abbott Laboratories
    Inventors: David A. Betebenner, Clarence J. Maring, Todd W. Rockway, Curt S. Cooper, David D. Anderson, Rolf Wagner, Rong Zhang, Akhteruzzaman Molla, Hongmei Mo, Tami J. Pilot-Matias, Sherie V L. Masse, Robert J. Carrick, Wenping He, Liangjun Lu
  • Publication number: 20120174324
    Abstract: The present invention relates to a dye of formula (I) where R1, R2, X, Y and t are each as defined in claim 1, to its preparation and to its use.
    Type: Application
    Filed: April 15, 2010
    Publication date: July 12, 2012
    Applicant: DYSTAR COLOURS DEUTSCHLAND GMBH
    Inventors: Roxana Barbieru, Werner Russ, Jürgen Kühlwein, Carsten Harfmann
  • Patent number: 8207172
    Abstract: The invention relates to novel heterocycles of formula (I) processes for their preparation and their use for preparing medicaments for the treatment or prophylaxis of disorders, especially of hyperproliferative disorders.
    Type: Grant
    Filed: August 19, 2005
    Date of Patent: June 26, 2012
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Chengzhi Zhang, Jacques Dumas, Qingming Zhu, Roger Smith, Qingjie Liu, Sharad Verma, Jason Duquette, Qian Zhao, Dongping Fan, Georgiy Bondar, Philip Coish
  • Patent number: 8193528
    Abstract: The present invention relates to electronic devices, especially electroluminescent devices, comprising azapyrenes of formula (I), or formula (III), wherein Y1, Y2, Y3, Y4, X1, X2 and X3 are independently each other N, or CR4, with the proviso that at least one of the groups X1, X2 and X3 is a group CR4, R1 is hydrogen, F, —SiR100R101R102, or an organic substituent, R4 is hydrogen, F, —SiR100R101R102, or an organic substituent, or any of the substituents R1, R1? and R4, which are adjacent to each other, together form an aromatic, or heteroaromatic ring, or ring system, which can optionally be substituted, m is an integer of 1 to 6, and R100, R101 and R102 are independently of each other a C1-C8alkyl group, a C6-C24aryl group, or a C7-C12aralkyl group, which may optionally be substituted, and Q is a linking group; with the proviso that in the compound of formula (III) at least one of the substituents R1, or R4 is a group Q; especially as host for phosphorescent emitters, electron transporting materials, or emit
    Type: Grant
    Filed: June 23, 2009
    Date of Patent: June 5, 2012
    Assignee: BASF SE
    Inventors: Thomas Schäfer, Thomas Eichenberger, Kristina Bardon, Andrea Ricci, Natalia Chebotareva
  • Publication number: 20120135978
    Abstract: A novel compound which is useful as an agent for treating and/or preventing emesis, vomiting and/or constipation. A compound represented by the formula (I): wherein R1 and R2 are each independently hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted cycloalkyl, optionally substituted aryl etc., R3 is hydrogen, hydroxy, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted lower alkoxy etc., R4 is hydrogen or lower alkyl, R5 is hydrogen, lower alkyl, cycloalkyl lower alkyl or lower alkenyl, or a pharmaceutically acceptably salt, or a solvate thereof is provided.
    Type: Application
    Filed: November 30, 2011
    Publication date: May 31, 2012
    Inventors: Masanao INAGAKI, Shin-ichiro Hara, Nobuhiro Haga, Yoshinori Tamura, Yoshihisa Goto, Tsuyoshi Hasegawa
  • Patent number: 8180572
    Abstract: The present invention relates to methods and systems for the analysis of the dissociation behavior of nucleic acids and the identification of nucleic acids. In one aspect, methods and systems are disclosed for resolving a denaturation curve of a sample containing a first and second nucleic acid into a resolved denaturation curve for the first nucleic acid and a resolved denuration curve for the second nucleic acid.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: May 15, 2012
    Assignee: Canon U.S. Life Sciences, Inc.
    Inventor: Weidong Cao
  • Publication number: 20120094987
    Abstract: The invention relates to compounds of general formula (I); 1a, 1b, 1c and 1d. The invention also relates to a method for the production thereof, pharmaceutical preparations containing said compounds and/or physiologically compatible salts thereof which can be produced therefrom and/or solvates thereof, and to the pharmaceutical use of said compounds, salts or solvates thereof as inhibitors of phosphodiesterase 4. The compounds comprise active ingredients for the treatment of diseases which can have a positive influence by inhibiting the activity of phosphodiesterase 4 and/or TNF?-release, for example, in lymphocytes, eosinophile and basophile granulocytes, macrophages and mastocytes.
    Type: Application
    Filed: October 3, 2011
    Publication date: April 19, 2012
    Inventors: Claudia Reichelt, Alexander Ludwig, Alexander Schulze, Mohammed Daghish, Siegfried Leistner, Andreas Krödel, Jochen Heinicke
  • Patent number: 8145433
    Abstract: The present invention relates to methods and systems for the analysis of the dissociation behavior of nucleic acids and the identification of nucleic acids. In one aspect, methods and systems are disclosed for identifying a nucleic acid in a sample including an unknown nucleic acid and for detecting a single nucleotide polymorphism in a nucleic acid in a sample. In another aspect, methods and systems are disclosed for identification of a nucleic acid in a biological sample including at least one unknown nucleic acid by fitting denaturation data including measurements of a quantifiable physical change of the sample at a plurality of independent sample property points to a function to determine an intrinsic physical value and to obtain an estimated physical change function, and identifying the nucleic acid in the biological sample by comparing the intrinsic physical value for at least one unknown nucleic acid to an intrinsic physical value for a known nucleic acid.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: March 27, 2012
    Assignee: Canon U.S. Life Sciences, Inc.
    Inventors: Deborah Boles, Kenton C. Hasson, Sami Kanderian
  • Patent number: 8143255
    Abstract: The present invention relates to pyrimidine compounds that are useful as anti-proliferative agents. More particularly, the present invention relates to heteroalkyl linked and substituted pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative disorders including tumors and cancers as well as other conditions or disorders associated with kinases.
    Type: Grant
    Filed: November 15, 2006
    Date of Patent: March 27, 2012
    Assignee: S*BIO Pte Ltd.
    Inventors: Stephanie Blanchard, Kantharaj Ethirajulu, Cheng Hsia Angeline Lee, Harish Kumar Mysore Nagaraj, Anders Poulsen, Eric T. Sun, Yee Ling Evelyn Tan, Ee Ling Teo, Anthony Deodaunia William